Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Yes. Nurse practitioners can prescribe peptides in every state, under the same prescriptive authority that covers any prescription drug. Whether a given NP can prescribe a given peptide turns on four checks: practice authority, the agreement or formulary, the product's legal pathway, and where the patient is.
Yes. Nurse practitioners can prescribe peptides in all 50 states and DC, because a peptide used as a drug falls under the same prescriptive authority that lets an NP prescribe any other prescription drug, and no state requires a separate peptide license or certification.
Whether a particular NP can prescribe a particular peptide to a particular patient is a narrower question, and it is the one that gets NPs into trouble. Four checks decide it: how the state structures NP practice, what the NP's collaborative agreement or formulary covers, whether the product itself has a lawful pathway, and which state the patient is located in. This guide takes each in turn, then covers what to write into a collaborative agreement before the first peptide prescription.
Status as of October 20, 2026. Practice authority follows the American Association of Nurse Practitioners' 2026 State Practice Environment. For every state's classification and the statute behind it, see the 50-state table in our guide to who can prescribe peptides.
| Check | Where the answer lives | How it fails |
|---|---|---|
| Practice authority | State nurse practice act and board of nursing rules | The NP has not finished a required transition period, or practices in a setting the state excludes from independent practice |
| Agreement or formulary | The collaborative agreement, protocol, or state formulary | The agreement lists drug categories that leave out compounded injectables or peptide therapy |
| Product | FDA approval, or the federal compounding rules | The product is a research use only peptide, or a compound whose bulk substance does not qualify |
| Patient location | The licensing rules of the state where the patient sits | The NP treats a patient in a state where the NP holds no license, often by telehealth |
An NP who clears all four can prescribe the peptide. Failing any one of them leaves the NP without authority, however strong the NP's training.
AANP sorts states into three practice environments. In the 27 full practice states and DC, NPs evaluate, diagnose, and prescribe under the authority of the board of nursing alone, though many of these states first require a transition period of collaborative or supervised practice, from 750 hours in Colorado to 3,600 hours in New York. In the 12 reduced practice states, state law requires a career-long collaborative agreement with a physician for at least one element of practice. In the 11 restricted practice states, it requires career-long supervision, delegation, or team management by a physician.
Peptides rarely raise the controlled substance limits that dominate NP scope debates. Most therapeutic peptides are not scheduled under the federal Controlled Substances Act, so Schedule II restrictions and DEA registration do not usually apply to them. The question that matters for peptides is whether the state requires a physician relationship, and what that relationship says.
Full practice is also narrower in some states than the label suggests. Florida's autonomous APRN registration is the clearest example. Under Fla. Stat. 464.0123(3), an autonomous APRN may practice independently "only in primary care practice, including family medicine, general pediatrics, and general internal medicine." A peptide program run inside a med spa, aesthetic practice, or longevity clinic should assume it sits outside primary care and keep a supervising physician protocol in place unless the Florida Board of Nursing says otherwise.
In reduced and restricted states, the document the NP practices under decides the peptide question. A prescription the agreement does not cover is a prescription the NP has no authority to write, even in a state that lets NPs prescribe peptides in general.
Three states show how differently that document can work.
Texas. NPs prescribe under a prescriptive authority agreement with a physician, and Tex. Occ. Code 157.0512 requires the agreement to identify the types or categories of drugs or devices the NP may prescribe, or those the NP may not. An agreement drafted for a primary care practice may list categories that leave compounded injectables out, or exclude them outright. Our Texas guide covers the delegation and med spa rules that sit on top of it.
California. NPs furnish drugs under standardized procedures with a supervising physician and need a furnishing number, unless they have qualified as 103 or 104 NPs after a transition to practice. Peptides have to fall within the standardized procedures. Our California guide covers the state's good-faith exam rule and pharmacy law.
Alabama. Certified registered nurse practitioners prescribe only legend drugs on a formulary adopted by the Board of Nursing and the Board of Medical Examiners, under a protocol signed with a collaborating physician (Ala. Admin. Code 540-X-8-.11). Off-label prescribing is allowed only when it is within the standard of care, supported by evidence, approved by the collaborating physician, and entered in the patient record. The same rule limits drugs without FDA approval to IRB-registered or expanded access clinical trials. An Alabama NP should get the boards' position in writing before prescribing any compounded peptide.
Prescriptive authority only reaches products with a lawful pathway into patient care. For peptides there are two.
FDA-approved peptide drugs. An NP may prescribe an approved peptide drug for its labeled indication, and off label where state law and the agreement allow it.
Compounded peptides. A 503A pharmacy may compound a drug on the prescription of "a licensed physician or other licensed practitioner authorized by State law to prescribe drugs" (21 U.S.C. 353a). That language includes NPs with prescriptive authority. The bulk substance still has to qualify, which is a moving target; our map of the FDA compounding categories tracks it.
Research use only peptides have no pathway at all, and the Alabama Board of Medical Examiners issued an official notice saying so for NPs in plain terms: "no CNM, CRNP, or PA is legally authorized to prescribe, administer, advise, or dispense a non-FDA-approved or research grade peptide." The notice also closes the most common workaround. Consent forms "purporting to identify a product as 'research-grade' are ineffective and do not mitigate or eliminate the health care provider's professional or legal liability." Other boards have not all said it as directly, but no state treats a research use only vial as a lawful prescription drug. Our US guide to peptide legality explains why.
Growth hormone is the one peptide hormone with a federal rule written around physicians. Under 21 U.S.C. 333(e), distributing human growth hormone is a felony unless it is for an FDA-authorized condition and "pursuant to the order of a physician." An NP who prescribes somatropin, even for an approved indication, should get a legal opinion on how that language applies first. Growth hormone secretagogues are separate drugs and fall outside the statute.
An NP needs an NP license in the state where the patient is located at the time of care, including for a telehealth visit. Two compacts get confused here. The Nurse Licensure Compact covers RN and LPN licenses only, so a multistate RN license does not extend NP prescribing. The APRN Compact, which would, has been enacted in four states and does not take effect until seven have enacted it (Del. Code tit. 24, 1911B). Until then, an NP running a multistate telehealth peptide program needs a separate license, and in reduced and restricted states a separate agreement, for each state served.
An NP adding peptides in a reduced or restricted state should amend the agreement before the first prescription, not after. These are the provisions that matter.
| Provision | What it should say |
|---|---|
| Drug categories | Names compounded injectable peptides and the approved peptide drugs the NP will prescribe, not just "prescription drugs" |
| Off-label use | States whether off-label prescribing is authorized and what documentation it requires |
| Sourcing | Limits orders to licensed 503A pharmacies or registered 503B outsourcing facilities, and rules out research use only suppliers |
| Evaluation and consent | Requires a documented exam, indication, and informed consent covering regulatory status and evidence |
| Monitoring | Sets baseline and follow-up labs by therapy class, and when the NP consults the physician |
| Chart review | Sets how often the physician reviews peptide charts and how that review is recorded |
Physicians who sign these agreements carry their own exposure. The Alabama notice says a physician "may not circumvent his or her duty of care to patients by permitting or delegating" prohibited prescribing to an NP or PA. A specific agreement protects both clinicians.
No. Authority comes from the NP license and, where the state requires one, the agreement. A certification gives a licensed NP the clinical and regulatory knowledge to prescribe peptides to the standard of care: indications, dosing, contraindications, monitoring, sourcing, and documentation. Boards judge prescriptions against that standard, so documented, accredited training supports an NP's position if a prescription is ever questioned. Our peptide course for nurses and nurse practitioners carries 20 ANCC contact hours, and our guide to peptide CME for NP recertification covers how those hours count toward ANCC and AANPCB renewal.
In the 27 full practice states and DC, yes, once any required transition period is complete. In the 23 reduced and restricted states, NPs prescribe peptides under a collaborative agreement, protocol, or supervision arrangement with a physician, and that document has to cover them.
Yes. Federal law lets a 503A pharmacy compound on the prescription of any practitioner authorized by state law to prescribe, which includes NPs. The bulk substance has to qualify under the FDA compounding rules, and in states like Alabama, the formulary and protocol have to allow it.
No. Research use only peptides are not lawful prescription drugs in any state. Alabama's medical board has said directly that no NP is authorized to prescribe, administer, or even advise on them, and that a patient consent form does not change that.
Usually not for the peptide itself, because most therapeutic peptides are not federally controlled substances. An NP needs DEA registration for any scheduled drug in the same program, such as testosterone, which is Schedule III.
Only with an NP license in the patient's state. The Nurse Licensure Compact does not cover NP practice, and the APRN Compact is not yet in effect.
No. Prescriptive authority comes from the NP license and state law. Certification and accredited CME supply the clinical knowledge to prescribe to the standard of care and the documentation that shows it.